Yes to Adjuvant Chemotherapy in EGFR Mutated NSCLC
During ELCC23, a controversial session was held where opponents debated the efficacy of adjuvant chemotherapy for patients with EGFR-mutated NSCLC. Listen to the ”YES” opponent Benjamin Besse from the Gustave Roussy Cancer Campus in France, summarizing his arguments from the session in favor of adjuvant chemotherapy.
